Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay

Sheng Tong; Qing Chen; Si Qing Shan; Mark W. Dewhirst; Fan Yuan

doi:10.1007/s10456-006-9029-x

Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay

Sheng Tong
, Qing Chen
, Si Qing Shan
, Mark W. Dewhirst
, Fan Yuan

Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

GW5638 is a novel tissue-selective estrogen receptor (ER) modulator. Structurally, it is a derivative of tamoxifen that is known for its inhibitory effects on angiogenesis in an ER-independent manner. Therefore, it is possible that GW5638 has the same effects as tamoxifen on angiogenesis. To test this hypothesis, we used the rat cornea pocket assay and developed a new method that could precisely determine the total projected area of microvessels induced by basic fibroblast growth factor (bFGF) in the cornea. Animals in the study were treated with corn oil (control group), tamoxifen, or GW5638. After treatment, we observed that both GW5638 and tamoxifen could inhibit angiogenesis in the cornea (P<0.05) and that the inhibitory effects were not mediated by blocking functions of estrogen. Meanwhile, GW5638 had minimal effects on the body weight of animals whereas tamoxifen significantly reduced the body weight. Based on these observations, we concluded that GW5638 was as effective as tamoxifen in antiangiogenic treatment but less toxic than tamoxifen.

Original language	English
Pages (from-to)	53-58
Number of pages	6
Journal	Angiogenesis
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s10456-006-9029-x
State	Published - Jun 2006

Bibliographical note

Funding Information:
The authors would like to thank Dr. Donald P. McDonnell for scientific discussion. The work supported in part by a grant from the Department of Defense (BC980191).

Funding

The authors would like to thank Dr. Donald P. McDonnell for scientific discussion. The work supported in part by a grant from the Department of Defense (BC980191).

Funders	Funder number
U.S. Department of Defense	BC980191

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Angiogenesis
Cornea pocket assay
DPC974
Estrogen receptor-modulator
GW5638

ASJC Scopus subject areas

Physiology
Clinical Biochemistry
Cancer Research

Access to Document

10.1007/s10456-006-9029-x

Cite this

@article{166f5862fb094f5c9f91a0758c586daa,

title = "Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay",

abstract = "GW5638 is a novel tissue-selective estrogen receptor (ER) modulator. Structurally, it is a derivative of tamoxifen that is known for its inhibitory effects on angiogenesis in an ER-independent manner. Therefore, it is possible that GW5638 has the same effects as tamoxifen on angiogenesis. To test this hypothesis, we used the rat cornea pocket assay and developed a new method that could precisely determine the total projected area of microvessels induced by basic fibroblast growth factor (bFGF) in the cornea. Animals in the study were treated with corn oil (control group), tamoxifen, or GW5638. After treatment, we observed that both GW5638 and tamoxifen could inhibit angiogenesis in the cornea (P<0.05) and that the inhibitory effects were not mediated by blocking functions of estrogen. Meanwhile, GW5638 had minimal effects on the body weight of animals whereas tamoxifen significantly reduced the body weight. Based on these observations, we concluded that GW5638 was as effective as tamoxifen in antiangiogenic treatment but less toxic than tamoxifen.",

keywords = "Angiogenesis, Cornea pocket assay, DPC974, Estrogen receptor-modulator, GW5638",

author = "Sheng Tong and Qing Chen and Shan, \{Si Qing\} and Dewhirst, \{Mark W.\} and Fan Yuan",

note = "Funding Information: The authors would like to thank Dr. Donald P. McDonnell for scientific discussion. The work supported in part by a grant from the Department of Defense (BC980191).",

year = "2006",

month = jun,

doi = "10.1007/s10456-006-9029-x",

language = "English",

volume = "9",

pages = "53--58",

number = "2",

}

TY - JOUR

T1 - Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay

AU - Tong, Sheng

AU - Chen, Qing

AU - Shan, Si Qing

AU - Dewhirst, Mark W.

AU - Yuan, Fan

N1 - Funding Information: The authors would like to thank Dr. Donald P. McDonnell for scientific discussion. The work supported in part by a grant from the Department of Defense (BC980191).

PY - 2006/6

Y1 - 2006/6

N2 - GW5638 is a novel tissue-selective estrogen receptor (ER) modulator. Structurally, it is a derivative of tamoxifen that is known for its inhibitory effects on angiogenesis in an ER-independent manner. Therefore, it is possible that GW5638 has the same effects as tamoxifen on angiogenesis. To test this hypothesis, we used the rat cornea pocket assay and developed a new method that could precisely determine the total projected area of microvessels induced by basic fibroblast growth factor (bFGF) in the cornea. Animals in the study were treated with corn oil (control group), tamoxifen, or GW5638. After treatment, we observed that both GW5638 and tamoxifen could inhibit angiogenesis in the cornea (P<0.05) and that the inhibitory effects were not mediated by blocking functions of estrogen. Meanwhile, GW5638 had minimal effects on the body weight of animals whereas tamoxifen significantly reduced the body weight. Based on these observations, we concluded that GW5638 was as effective as tamoxifen in antiangiogenic treatment but less toxic than tamoxifen.

AB - GW5638 is a novel tissue-selective estrogen receptor (ER) modulator. Structurally, it is a derivative of tamoxifen that is known for its inhibitory effects on angiogenesis in an ER-independent manner. Therefore, it is possible that GW5638 has the same effects as tamoxifen on angiogenesis. To test this hypothesis, we used the rat cornea pocket assay and developed a new method that could precisely determine the total projected area of microvessels induced by basic fibroblast growth factor (bFGF) in the cornea. Animals in the study were treated with corn oil (control group), tamoxifen, or GW5638. After treatment, we observed that both GW5638 and tamoxifen could inhibit angiogenesis in the cornea (P<0.05) and that the inhibitory effects were not mediated by blocking functions of estrogen. Meanwhile, GW5638 had minimal effects on the body weight of animals whereas tamoxifen significantly reduced the body weight. Based on these observations, we concluded that GW5638 was as effective as tamoxifen in antiangiogenic treatment but less toxic than tamoxifen.

KW - Angiogenesis

KW - Cornea pocket assay

KW - DPC974

KW - Estrogen receptor-modulator

KW - GW5638

UR - https://www.scopus.com/pages/publications/33748982200

UR - https://www.scopus.com/pages/publications/33748982200#tab=citedBy

U2 - 10.1007/s10456-006-9029-x

DO - 10.1007/s10456-006-9029-x

M3 - Article

C2 - 16622786

AN - SCOPUS:33748982200

SN - 0969-6970

VL - 9

SP - 53

EP - 58

JO - Angiogenesis

JF - Angiogenesis

IS - 2

ER -

Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this